3 March 2020
("Physiomics") or (the "Company")
Physiomics awarded two further contracts by Bicycle Therapeutics
Physiomics plc (AIM: PYC), the oncology consultancy using mathematical models and its Virtual Tumour™ technology to support the development of cancer treatment regimens and personalised medicine solutions, is pleased to announce that it has been awarded two further contracts of undisclosed value with its existing client Bicycle Therapeutics ("Bicycle"), building on the two projects announced in 2019.
Last year Physiomics worked with Bicycle on BT1718, its lead programme currently in a Cancer Research UK-sponsored Phase I/IIa clinical in solid tumours. Physiomics' role related to the analysis of clinical data from this trial, and the Company's work was acknowledged in a poster presentation at the ESMO conference in September 2019(1). Separately, Physiomics also worked with Bicycle on the mathematical modelling of interactions between tumour and Bicycle compounds in an immune-oncology setting, which at the time of its announcement was the fourth project conducted by Physiomics in the immune-oncology space.
The projects announced today will involve pharmacokinetic and pharmacodynamic analysis of a number of Bicycle compounds and build on work completed by the Company previously. Both projects are expected to be completed in the next six months.
Dr Jim Millen, CEO said: "We are delighted to be working with Bicycle Therapeutics again in 2020 and believe that we are contributing significantly to key development decisions. It is particularly interesting to be working with Bicycle at a time when it is forging close relationships with large cap pharma companies as evidenced by the recent announcement of a significant new deal with US giant Genentech(2)"
Dr Jim Millen, CEO
+44 (0)1865 784 980
Strand Hanson Ltd (NOMAD)
Richard Tulloch & James Dance
+44 (0) 20 7409 3494
Hybridan LLP (broker)
Claire Louise Noyce
+44 (0) 203 764 2341
Notes to Editor
Physiomics plc (AIM: PYC) is a provider of technology-based solutions to predict the effects of cancer treatment regimens for the biopharma industry. The Company's Virtual Tumour™ technology uses computer modelling to predict the effects of cancer drugs and treatments to improve the success rate of drug discovery and development projects while reducing time and cost. The predictive capability of Physiomics' technologies have been confirmed by over 70 projects, involving over 30 targets and 60 drugs, and has worked with clients such as Merck KGaA, Merck & Co, Bayer and Lilly.
Based in Oxford UK, the Company works with clients worldwide to support their pre-clinical and clinical oncology development programs. Its team of scientists and computer modelling experts provide bespoke solutions encompassing data, analytics and insight.
Physiomics senior management has academic and commercial expertise, including over 120 years collectively of working in oncology and/or computational biology and over 120 publications in peer reviewed journals that have attracted thousands of citations.